マーケットレポート詳細
お問い合わせは、アイコンをクリックしてご入力ください。別タブでフォームが開きます。
当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。
デュシェンヌ型筋ジストロフィー(DMD)治療の世界市場規模は2023年で22億ドル、2034年に74億ドル、市場の平均年成長率は11.7%にて増加する見込みです。
当レポートでは、デュシェンヌ型筋ジストロフィー(DMD)治療の市場予測-2034年、各種セグメント別市場分析(治療タイプ別、エンドユーザー別、国地域別、等)、主要製品/ブランド分析
主要な合併、買収、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
■デュシェンヌ型筋ジストロフィー(DMD)治療の世界市場予測2020-2034年
・市場規模(US$)
■治療タイプ別、市場-2034年
・分子療法
・ステロイド療法
・非ステロイド性抗炎症薬(NSAIDs)
・理学療法
・その他(手術など)
※(市場規模US$)
■エンドユーザー別、市場-2034年
・病院
・専門クリニック
・その他(研究機関など)
※(市場規模US$)
■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照
■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収
■デュシェンヌ型筋ジストロフィー(DMD)治療の主要企業プロフィール動向
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Fresenius Kabi AG
Hikma Pharmaceuticals plc
Novartis AG
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
GSK plc
Bayer AG
Sun Pharmaceutical Industries Ltd.
Boehringer Ingelheim
Sanofi
Sarepta Therapeutics, Inc.
(全167頁)
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Duchenne Muscular Dystrophy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Molecular-based Therapies
6.3.2. Steroid Therapy
6.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
6.3.4. Physical Therapy
6.3.5. Others (Surgery, etc.)
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Others (Research Institutes, etc.)
7.4. Market Attractiveness Analysis, by End-user
8. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Duchenne Muscular Dystrophy Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2020-2034
9.3.1. Molecular-based Therapies
9.3.2. Steroid Therapy
9.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
9.3.4. Physical Therapy
9.3.5. Others (Surgery, etc.)
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Others (Research Institutes, etc.)
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment Type
9.6.2. By End-user
9.6.3. By Country
10. Europe Duchenne Muscular Dystrophy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2020-2034
10.3.1. Molecular-based Therapies
10.3.2. Steroid Therapy
10.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
10.3.4. Physical Therapy
10.3.5. Others (Surgery, etc.)
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others (Research Institutes, etc.)
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Duchenne Muscular Dystrophy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2020-2034
11.3.1. Molecular-based Therapies
11.3.2. Steroid Therapy
11.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
11.3.4. Physical Therapy
11.3.5. Others (Surgery, etc.)
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others (Research Institutes, etc.)
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Duchenne Muscular Dystrophy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2020-2034
12.3.1. Molecular-based Therapies
12.3.2. Steroid Therapy
12.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.3.4. Physical Therapy
12.3.5. Others (Surgery, etc.)
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others (Research Institutes, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Duchenne Muscular Dystrophy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2020-2034
13.3.1. Molecular-based Therapies
13.3.2. Steroid Therapy
13.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.3.4. Physical Therapy
13.3.5. Others (Surgery, etc.)
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others (Research Institutes, etc.)
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Mylan N.V.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Fresenius Kabi AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Hikma Pharmaceuticals plc
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Novartis AG
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Teva Pharmaceutical Industries Ltd.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Bristol Myers Squibb Company
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. GSK plc
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Bayer AG
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
14.3.11. Sun Pharmaceutical Industries Ltd.
14.3.11.1. Company Overview
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Financial Overview
14.3.11.5. Strategic Overview
14.3.12. Boehringer Ingelheim
14.3.12.1. Company Overview
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Financial Overview
14.3.12.5. Strategic Overview
14.3.13. Sanofi
14.3.13.1. Company Overview
14.3.13.2. Product Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Financial Overview
14.3.13.5. Strategic Overview
14.3.14. Sarepta Therapeutics, Inc.
14.3.14.1. Company Overview
14.3.14.2. Product Portfolio
14.3.14.3. SWOT Analysis
14.3.14.4. Financial Overview
14.3.14.5. Strategic Overview
List of Tables
Table 01: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 02: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 03: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 04: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 05: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 06: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 07: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 09: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 10: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 12: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 15: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 18: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Duchenne Muscular Dystrophy Market Revenue (US$ Bn), by Treatment Type, 2023
Figure 03: Global Duchenne Muscular Dystrophy Market Value Share, by Treatment Type, 2023
Figure 04: Global Duchenne Muscular Dystrophy Market Revenue (US$ Bn), by End-user, 2023
Figure 05: Global Duchenne Muscular Dystrophy Market Value Share, by End-user, 2023
Figure 06: Global Duchenne Muscular Dystrophy Market Value Share, by Region, 2023
Figure 07: Global Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast, 2020-2034
Figure 08: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 09: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 10: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 11: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 12: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by Region, 2023 and 2034
Figure 13: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Region, 2023-2034
Figure 14: North America Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country, 2023-2034
Figure 16: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by Country, 2023 and 2034
Figure 17: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 18: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 19: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 20: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 21: Europe Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 22: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 23: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 24: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 25: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 26: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 27: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 28: Asia Pacific Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 29: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 30: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 31: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 32: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 34: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 35: Latin America Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 36: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 37: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 38: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 39: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 41: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 42: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 43: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 44: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 45: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 46: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 47: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 48: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034